文献速递骨质疏松与代谢性骨病创伤骨科

评估基因谱在骨折风险预测中的临床效用:决策曲线分析

Assessing the clinical utility of genetic profiling in fracture risk prediction: a decision curve analysis.
PubMed 文献 · Osteoporos Int · 2020-08-12

研究纳入2188名女性和1324名男性、年龄60岁及以上、随访最长23年,用决策曲线分析评估由62个基因变异构建的骨基因组谱对骨折风险预测的临床净获益。结果显示全模型GFRC+GRS净获益最高;在女性10年风险阈值>18%、男性>15%时,GRS在CRF模型之上提供净获益;20%阈值时加用GRS相比Garvan模型可分别避免每81名女性或每24名男性中的1例额外治疗。结论认为在较高风险阈值下基因谱可改善净临床获益,尽管在BMD+CRF存在时贡献有限,但似乎能够替代BMD用于骨折预测。

要点

  • 在2188名女性和1324名男性中,全模型GFRC+GRS在女性和男性中均取得最高净获益。
  • 女性10年风险阈值>18%、男性>15%时,GRS在CRF模型之上提供净获益。
  • 20%风险阈值时,相比Garvan模型加用GRS可避免每81名女性或每24名男性中的1例额外治疗。

核心结论

  • 将基因谱加入临床危险因素可在较高骨折风险阈值下改善净临床获益。
  • 尽管在BMD+CRF存在时基因谱贡献有限,但似乎能够替代BMD用于骨折预测。

研究设计与样本

  • 研究纳入2188名女性和1324名男性,年龄60岁及以上,随访最长23年。
  • 基线获取骨密度(BMD)和临床危险因素,记录骨折发生率和死亡率。
  • 由62个BMD相关基因变异构建加权个体遗传风险评分(GRS)。
  • 比较四个模型:CRF(临床危险因素)、CRF+GRS、包含CRF和股骨颈BMD的Garvan模型(GFRC)、GFRC+GRS。
  • 采用决策曲线分析(DCA)在一系列临床合理风险阈值下评估预测模型的临床净获益。

主要发现

  • 在女性和男性中,全模型GFRC+GRS均取得最高净获益。
  • 女性10年风险阈值>18%、男性>15%时,GRS在CRF模型之上提供净获益。
  • 20%风险阈值时,相比Garvan模型加用GRS可避免每81名女性或每24名男性中的1例额外治疗。
  • 在较低风险阈值下,四个模型之间无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Using decision curve analysis on 2188 women and 1324 men, we found that an osteogenomic profile constructed from 62 genetic variants improved the clinical net benefit of fracture risk prediction over and above that of clinical risk factors and BMD. INTRODUCTION: Genetic profiling is a promising tool for assessing fracture risk. This study sought to use the decision curve analysis (DCA), a novel approach to determine the impact of genetic profiling on fracture risk prediction. METHODS: The study involved 2188 women and 1324 men, aged 60 years and above, who were followed for up to 23 years. Bone mineral density (BMD) and clinical risk factors were obtained at baseline. The incidence of fracture and mortality were recorded. A weighted individual genetic risk score (GRS) was constructed from 62 BMD-associated genetic variants. Four models were considered: CRF (clinical risk factors); CRF + GRS; Garvan model (GFRC) including CRF and femoral neck BMD; and GFRC + GRS. The DCA was used to evaluate the clinical net benefit of predictive models at a range of clinically reasonable risk thresholds. RESULTS: In both women and men, the full model GFRC + GRS achieved the highest net benefits. For 10-year risk threshold > 18% for women and > 15% for men, the GRS provided net benefit above those of the CRF models. At 20% risk threshold, adding the GRS could help to avoid 1 additional treatment per 81 women or 1 per 24 men compared with the Garvan model. At lower risk thresholds, there was no significant difference between the four models. CONCLUSIONS: The addition of genetic profiling into the clinical risk factors can improve the net clinical benefit at higher risk thresholds of fracture. Although the contribution of genetic profiling was modest in the presence of BMD + CRF, it appeared to be able to replace BMD for fracture prediction.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Ho-Le TP, Tran HTT, Center JR, et al. Assessing the clinical utility of genetic profiling in fracture risk prediction: a decision curve analysis. Osteoporos Int. 2020. PMID: 32789607. doi:10.1007/s00198-020-05403-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。